By considering an ongoing clinical trial using poly (ADP-ribose) polymerase (PARP) inhibitors on leiomyosarcoma, HR-related genes, including the RAD51D splicing variant identified in this case, can be a good clinical molecular marker not only for risk prediction but also for the choice of treatments for leiomyosarcoma. Here, RAD51D is linked to leiomyosarcoma.